Concepedia

Alessandro Lucchesi

AL

Statistics

Publications

33

Citations

1.4K

H-Index

20

Active since

2009

Affiliations

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

The University of Texas MD Anderson Cancer Center

University of Bologna

St. Eugenio Hospital

Alessandro Lucchesi is an author at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori specializing in medicine, clinical pharmacology, and pharmacology.

ORCID

Publications per year

2009–2025

33

Publications

33

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman İlhan, Won Sik Lee et al. · The Lancet Infectious Diseases · 2019 · 254 citations · Full text

, , +16

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

, , +9

Mathematical model of a proton-exchange membrane (PEM) fuel cell

Abdelnasir Omran, Alessandro Lucchesi, Abed Alaswad et al. · International Journal of Thermofluids · 2021 · 102 citations · Full text

, , +17

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Michele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso et al. · Blood Advances · 2019 · 89 citations · Full text

, , +11

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Stephen T. Oh, Ruben A. Mesa, Claire Harrison et al. · Blood Advances · 2023 · 73 citations · Full text

, , +5

1–5 of 33